TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9440372
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g fat meal
Study: 9440372
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fat meal
Study: 2151278
Drug: Zoladex depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex depot alone, 3.6 mg subcutaneously every 28 days
Study: 2151278
Drug: Zoladex depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex depot plus cyproterone acetate (CPA), 200 mg/day orally
Study: 345826
Drug: Phenelzine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (mean dose of 78 mg/day for 3 weeks)
Study: 29026385
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion and Saline infusion
Study: 25940554
Drug: 0.1 mg/ml
Normalized name: deanol 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/ml mitomycin-C (MMC) applied for 1 min
Study: 28720121
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders
Study: 16333854
Drug: PSA velocity
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA velocity <= 0.0 ng/mL per month
Study: 30192007
Drug: Rasagiline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 2 mg/day
Study: 10408537
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (IFN‐beta) 3 MIU for 2 weeks and then 6 MIU for 10 weeks, subcutaneously three times weekly
Study: 12000349
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health care education programme (OHCE)
Study: 2085969
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg single oral dose
Study: 25728546
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl citrate
Study: 25693333
Drug: Sugammadex 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 0.5 mg kg‐1
Study: 25693333
Drug: Sugammadex 8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 8.0 mg kg‐1
Study: 16887854
Drug: Achievement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achievement of NCEP LDL-C goal <1.8 mmol/L
Study: 15362593
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) with atropine (0.01 mg/kg I.M. administered 15 min prior to acetaminophen ingestion)
Study: 15362593
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) alone
Study: 11115081
Drug: PEG-hirudin (PEG-Hi)
Normalized name: hirudin
DrugBank: Pegmusirudin (DB19220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-hirudin (PEG-Hi) 0.05 mg/kg body weight, single intravenous bolus injection
Study: 6358278
Drug: Suberythemal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suberythemal dose of UVB or UVA radiation
Study: 27402064
Drug: Lulizumab pegol
Normalized name: Lulizumab pegol
DrugBank: Lulizumab pegol (DB15441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lulizumab pegol (SC; 6.25 mg every 2 weeks, 12.5 mg weekly, 37.5 mg weekly)
Study: 25439501
Drug: Facilitated Lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated Lifestyle Intervention Prescription (FLIP)
Study: 22230419
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (isotonic) solution
Study: 15504380
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral mifepristone followed by 400 microg oral misoprostol 2 days later
Study: 11468134
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (10 mg, i.m. injection every second week for 6 months)
Study: 11468134
Drug: Placebo (i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (i.m. injection every second week for 6 months)
Study: 18640991
Drug: ET-1 infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 infusion
Study: 24624849
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.2-1.4 microg kg(‐1) per hour)
Study: 21471823
Drug: Estrogen (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (0.625 mg conjugated estrogens)
Study: 17364275
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg bid for 16 weeks
Study: 7768078
Drug: Melatonin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.3 mg or 1.0 mg)
Study: 28091703
Drug: Landiolol (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.1, 0.2, and 0.3 mg/kg BW)
Study: 28091703
Drug: Esmolol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5, 1, and 1.5 mg/kg BW)
Study: 26560483
Drug: Dexamethasone 1.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.65 mg
Study: 31750699
Drug: No-treatment (NT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment (NT)
Study: 3511209
Drug: 3-week benzathine
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week benzathine penicillin G injections
Study: 3511209
Drug: 4-week benzathine
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week benzathine penicillin G injections
Study: 31690523
Drug: Intermittent vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent vacuum therapy (IVT) at -50 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.
Study: 31690523
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment at -5 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.
Study: 8489087
Drug: Gentamicin admixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin admixed with clindamycin 900 mg IVPB every 8 hours (Group I n = 80)
Study: 2674460
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of cisplatin (CDDP)/m2
Study: 2674460
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of carboplatin (CBDCA)/m2
Study: 31122824
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (Moviprep® after capsule arrival)
Study: 24013058
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly for 26 weeks
Study: 25394366
Drug: Sequential pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pattern recognition control
Study: 23546562
Drug: Control (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (24 weeks of monthly weigh-ins)
Study: 20951487
Drug: Cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet plus low-dose activated vitamin D analogues (Cinacalcet-D)
Study: 7543713
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 units 2 hours before operation and 5000 units every 8 hours for 5 days after operation)
Study: 7543713
Drug: Dextran 40
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40 (administered during the operation with an additional infusion of 500 ml/day for the next 3 days)
Study: 2795401
Drug: Parent absent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent absent during injection
Study: 24740662
Drug: High-dosage tamoxifen
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage tamoxifen (80 mg/day) administered from six weeks prior until twelve weeks after surgery
Study: 22147649
Drug: MDX-1100 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDX-1100 (10 mg/kg every other week)
Study: 16334120
Drug: Weekly 1‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 1‐h or 3‐h infusions of paclitaxel
Study: 11986448
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension, 0.5 mg daily (n = 168)
Study: 9535299
Drug: Minimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal therapy (control)
Study: 7893023
Drug: edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 1 mg/kg + atropine 10 micrograms/kg, i.v.
Study: 27576860
Drug: CLT-28643 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLT-28643 (single subconjunctival injection intraoperatively) followed by postoperative vehicle eye drops (CLT+ group)
Study: 21494892
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 75 mg
Study: 26293513
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR (50 and 75 mg)
Study: 21928240
Drug: Brachial plexus
Normalized name: Brachial Plexus Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachial plexus block (BPB) with 15 mL ropivacaine 1% and 10 mL saline via axillary approach
Study: 17463075
Drug: TENS application
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS application for 60 minutes daily
Study: 17463075
Drug: TENS application
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS application for 8 hours daily
Study: 18728907
Drug: 2.5 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 hours of weekly, mandatory physical exercise of middle-to-high intensity
Study: 18728907
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of full-time weekly workhours from 40 to 37.5 hours
Study: 10234600
Drug: Argatroban 1
Normalized name: argatroban 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 1 microgram/kg/min infused on day 6 of a 7-day oral regimen of 500 mg erythromycin four times daily (regimen B)
Study: 1534993
Drug: 3 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms/ml sufentanil in saline (Group S)
Study: 1534993
Drug: 1.5 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 micrograms/ml sufentanil in 0.125% bupivacaine (Group SB)
Study: 3456271
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m2 iv every 3 weeks)
Study: 3456271
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2 iv every 3 weeks)
Study: 18231884
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injections
Study: 15662234
Drug: Up-titrated candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titrated candesartan (12 mg/day) monotherapy
Study: 12693152
Drug: Intramuscular HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular HBV vaccine (20 micrograms each dose) at 0, 1, and 6 month intervals
Study: 12693152
Drug: Intradermal HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal HBV vaccine (2 micrograms each dose) at 0, 1, and 6 month intervals
Study: 31377160
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) alone
Study: 28647759
Drug: Weekly mailings
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly mailings of parenting information (control)
Study: 9568453
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 mg twice daily
Study: 7778530
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg twice daily
Study: 30516797
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus enhanced medication management
Study: 29189347
Drug: Exenatide (17.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (17.4 μg infusion for 6 hours and 15 minutes)
Study: 26690312
Drug: Latest generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latest generation drug-eluting stent (SYNERGY™ II; Boston Scientific)
Study: 23032073
Drug: ABT-894 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-894 (4 mg BID)
Study: 23032073
Drug: Atomoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40 mg BID)
Study: 16152838
Drug: Vertebral manipulation
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebral manipulation (VM) therapy
Study: 10488597
Drug: Glutamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.3 g/kg enterally for 5 days)
Study: 10488597
Drug: Casein (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (0.3 g/kg enterally for 5 days)
Study: 8561067
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g butter
Study: 8561067
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g butter
Study: 1877740
Drug: Disulfiram (DS)
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram (DS) implant (10 x 100 mg DS tablets)
Study: 1877740
Drug: Disulfiram (DS)
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram (DS) implant
Study: 1877740
Drug: Placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9 x 100 mg calcium phosphate tablets + 1 mg DS tablet)
Study: 1888621
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel
Study: 1903813
Drug: Phenothrin lotion
Normalized name: phenothrin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenothrin lotion
Study: 9726802
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril 25 to 50 mg daily or enalapril 10 to 40 mg daily)
Study: 19759043
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing (ODD) of gentamicin
Study: 19759043
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dosing (MDD) of gentamicin
Study: 17726314
Drug: Moderate beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate beer consumption (330 ml for women and 660 ml for men) for 30 days
Study: 16335304
Drug: Cytokines with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines with antimicrobial agents
Study: 9501404
Drug: IVIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG infusion rate of 0.08 ml/kg/min
Study: 9501404
Drug: IVIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG infusion rate of 0.06 ml/kg/min
Study: 9501404
Drug: IVIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG infusion rate of 0.04 ml/kg/min
Study: 7995386
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ANP inhalation
Study: 7995386
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ANP inhalation
Study: 7995386
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ANP inhalation
Study: 2457768
Drug: Captopril 1
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 1 mg
Study: 2457768
Drug: Captopril 5
Normalized name: captopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 5 mg
Study: 21748252
Drug: ABT-089 40
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 40 mg QD
Study: 21748252
Drug: ABT-089 40
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 40 mg BID
Study: 21748252
Drug: ABT-089 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 (all doses)
Study: 16098001
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. (OCM group)
Study: 12182969
Drug: Pilocarpine (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5-mg tablets) three times daily for 1 month after treatment
Study: 12182969
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 1 month after treatment
Study: 23336124
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group observed the affected hand instead of using mirror therapy
Study: 1548648
Drug: Controlled-release ketoprofen
Normalized name: ketoprofen Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release ketoprofen
Study: 15699225
Drug: Statin diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin diet (20 mg lovastatin)
Study: 12971709
Drug: General programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: General programme of psychomotor therapy
Study: 30466402
Drug: Oxytocin (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (8.3 μg or 5 U)
Study: 15871654
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) methods applied to drug utilization patterns
Study: 12196660
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Semmes‐Weinstein monofilament (touch/pressure sensation)
Study: 11083193
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (4 mg in 5 minutes at admission, followed by 6 mg/hr over 24 hours)
Study: 9437273
Drug: Paracetamol-dextropropoxyphene
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol-dextropropoxyphene
Study: 3021501
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg q.i.d.
Study: 3021499
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2 mg q.i.d.
Study: 22490901
Drug: HNIPPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNIPPV plus tiotropium bromide and doxofylline tablets
Study: 22490901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tiotropium bromide, doxofylline tablets, and low-flow inhalation of oxygen)
Study: 18589554
Drug: Daidzein dripping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daidzein dripping pills (50 mg)
Study: 18589554
Drug: Daidzein tablets
DrugBank: Daidzein (DB13182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daidzein tablets (50 mg)
Study: 16078335
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg patch
Study: 12375713
Drug: Albuterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (200 microg, 2 inhalations via MDI with spacer)
Study: 1874224
Drug: Stepwise rising
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepwise rising propofol infusion regime of 0.24, 0.6 and 1.5 mg kg‐1 h‐1 for 75 min (25 min at each infusion rate)
Study: 19631948
Drug: Fluoxetine 20mg
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20mg
Study: 28463874
Drug: Conjugated estrogens/bazedoxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/bazedoxifene 0.45 mg/20 mg
Study: 28463874
Drug: Conjugated estrogens/bazedoxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/bazedoxifene 0.625 mg/20 mg
Study: 24748629
Drug: blisibimod 200
Normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: blisibimod 200 mg once-weekly (QW)
Study: 20237929
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (daily locally applied mud‐packs and bicarbonate‐sulphate mineral bath water)
Study: 19661449
Drug: Aminophylline (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (adenosine receptor antagonist)
Study: 21444699
Drug: MP-376 (levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-376 (levofloxacin inhalation solution) 180 mg
Study: 21444699
Drug: MP-376 (levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-376 (levofloxacin inhalation solution) 240 mg
Study: 21444699
Drug: MP-376 (levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-376 (levofloxacin inhalation solution)
Study: 8620638
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program (Group 2) designed to strengthen upper and lower limbs and improve knee range of motion
Study: 8620638
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 1) with no preoperative physical therapy
Study: 1458033
Drug: Bromocriptine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (1.25 mg bid)
Study: 6393460
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptive
Study: 6393460
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose oral contraceptive
Study: 29325799
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCY and hs-CRP
Study: 24618303
Drug: Montelukast tablets
Normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast tablets and fluticasone propionate nasal spray (n = 64)
Study: 12823079
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 100 mg daily)